Replies to post #97120 on Biotech Values

[turtlepower]

Thanks for the clarification. I think there are question marks on ACHN as well that I brought up in message
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51056707

The initiation of the POC trial of 320 also raises risks because of competition and perhaps I am being unduly bearish about how 320 would affect ACHN's chances of landing a partnership. I see a little bit of ARYX in ACHN where a lot rides on landing a partnership even though the comparison may not be fair considering ACHN at least has the money to run a clinical trial. IDIX is perhaps the safest small cap HCV play right now.